Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial

Journal:

The Lancet Neurology

Published:

2025-09-18

DOI:

10.1016/s1474-4422(25)00269-8

Affiliations:

18

Authors:

29

Go to article

Institutions	Authors	Share
Norwegian University of Science and Technology (NTNU), Norway	9.500000	0.33
Haukeland University Hospital, Norway	3.166667	0.11
St. Olavs Hospital (Trondheim University Hospital), NTNU, Norway	2.666667	0.09
UiO Akershus University Hospital (Ahus), Norway	2.500000	0.09
Oslo University Hospital (OUS), Norway	2.166667	0.07
Hospital of Southern Norway Trust, Norway	2.000000	0.07
Molde Hospital, Norway	2.000000	0.07
University of Bergen (UIB), Norway	1.666667	0.06
Nordland Hospital, Norway	1.000000	0.03
University Hospital of North Norway (UNN), Norway	1.000000	0.03
University of Tartu (UT), Estonia	0.500000	0.02
Tartu University Hospital, UT, Estonia	0.500000	0.02
University of Oslo (UiO), Norway	0.333333	0.01

Interested in Pharmacology and Pharmaceutical Sciences?